Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns.

The request followed three deaths potentially related to the gene therapy products. The deaths appeared to be the result of acute liver failure.

Click here to read the FDA’s press release.

Following investigation, the FDA reported that the death of an eight-year-old boy was not related to the gene therapy. The FDA recommended removal of the hold for ambulatory patients (patients who are still able to walk).

The FDA has said it will continue to work with Sarepta regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths.

Click here to read the further press release from the FDA.

On 24 July, the European Medicines Agency (EMA) issued a negative opinion of Elevidys, saying that the study “failed to show that Elevidys had an effect on movement abilities after 12 months”. The European regulator rejected the approval of the treatment. Click here to learn more.